Citations

Abstract Introduction The lower urinary tract injury, although often not life-threatening, can result in devastating long-term morbidity and, in some cases, permanent disability. Male genital trauma adversely affects male sexual function. Aim This 5th International Consultation on Sexual Medicine guideline on male genitalia trauma evaluates urologic trauma literature to guide clinicians in the best-evidenced management with specific emphasis on preservation and optimization of male sexual function. Methods A systematic literature search was conducted to identify relevant English-language publications and contemporary guidelines using the PubMed database (search dates January 1, 1990 to June 1, 2024) on the following terms: “trauma,” “penis,” “urethra,” “testis,” and “scrotum.” The available literature was discussed, and selected articles with the highest evidence available were used to create consensus guideline statements, categorized based on the Grading of Recommendations Assessment, Development and Evaluation system. In the absence of sufficient evidence, additional information was provided as a Clinical Principle or Expert Opinion. Results Fourteen recommendations are provided with corresponding levels of evidence and grades of recommendation. Conclusions Treating clinicians should be mindful that both the male genitalia trauma itself and treatment outcomes invariably affect various male sexual functions. Optimal treatment of male genitalia trauma is essential and should incorporate patient tolerances, needs, and preferences to minimize long-term sexual dysfunction.

A 59-year-old woman presented with a persistent, nonpruritic erythematous rash on both lower extremities. Dermoscopy showed petechiae and hemosiderin deposition, and biopsy revealed perivascular lymphocytic infiltration with red blood cell extravasation, confirming Schamberg disease. Laboratory studies were unremarkable. Minimal improvement with topical corticosteroids prompted addition of oral rutoside, ascorbic acid, and pentoxifylline, resulting in gradual fading of lesions. Schamberg disease is a benign, chronic pigmented purpuric dermatosis that can mimic vasculitis. Diagnosis requires clinical and histologic correlation, and management focuses on cosmetic improvement and patient reassurance regarding its nonprogressive nature.

Background: Lyme disease is the most common vector-borne disease in United States children. It was traditionally thought to be limited to the Northeast and upper Midwest due to the prevalence of tick and deer vectors in these regions. We hypothesize that as Lyme disease cases in children continue to increase throughout the country, nontraditional regions such as the Midwest and South may have an increased rate of Lyme disease compared with the Northeast region. Methods: The Pediatric Health Information System (PHIS) database was queried for patients 19.0 years or younger who were treated for Lyme disease between 2004 and 2019 through Emergency Department and in-patient records using ICD coding. Data from 49 pediatric hospitals was included and the centers were split into 4 regions based on geographic location. The data was separated into 2 time periods: 2004 to 2014 and 2015 to 2019. Slopes were compared using a general linear model with interaction to determine if annual rates of Lyme disease were statistically different between the 2 time periods. The data was then split by geographic region and again the annual rate of Lyme disease was compared between the 4 regions. A P -value <0.008 was considered significant to adjust for multiple comparisons. Results: Between 2004 and 2019, 7,572 cases of Lyme disease were reported with a mean age of 9.5 years (range: 0.08 to 19.00 y) and 58% male. From 2004 to 2019, there was an annual increase of 46.5 cases. When separated by region from 2004 to 2019, the Midwest had a higher increased annual rate of Lyme disease (30.7 additional cases/year) compared with the Northeast (10.0 additional cases/y), the South (3.6 additional cases/y), and the West (2.2 additional cases/y). Conclusions: Lyme disease continues to show an increased rate across the United States. The annual increase in cases in the Midwest was significantly higher than the other regions from 2004 to 2019. There does appear to be a significant regional spread, particularly in the Midwest. Awareness of the increased rate and spread of Lyme disease across the US is crucial in helping to identify national and regional strategies to diagnose and treat this disease in children. Level of Evidence: Level IV.

What is a coaching mindset? At its core is a conviction to agency: Learners are responsible for their own choices

Abstract INTRODUCTION Research is limited regarding meaningful change thresholds for individual patients on clinical outcome assessments (COAs) frequently used in clinical trials for Alzheimer's disease and related dementias (ADRD), particularly in population‐based studies early in the disease course. METHODS There were 646 study participants in the population‐based Mayo Clinic Study of Aging (MCSA), 54–99 years old (47% females), who developed the clinical syndromes of mild cognitive impairment (MCI) with complete data to establish clinically meaningful within‐patient change thresholds in cognitive and functional COAs. RESULTS Using the diagnosis of incident MCI as the anchor, mean (95% confidence interval [CI]) annualized estimates of change were: Clinical Dementia Rating (CDR) scale Sum of Boxes (SB) 0.49 (0.43, 0.55), Mini‐Mental State Examination (MMSE) −1.01 (−1.12, −0.91), and Functional Activities Questionnaire (FAQ) score 1.04 (0.82, 1.26). DISCUSSION This study provides within‐patient estimates of clinically meaningful change early in disease progression in a community‐based sample. Highlights We studied incident mild cognitive impairment (MCI) participants from a population‐based study. Within‐patient change thresholds were estimated for clinical outcome assessments (COAs) used in clinical trials for Alzheimer's disease and related dementia (ADRD). These estimates may be used to plan and evaluate clinical trials involving disease‐modifying therapies (DMTs).

ABSTRACT Background Ureteral stents are commonly placed during kidney transplantation (KT) to mitigate urologic complications. The objective of this study was to compare clinical outcomes in KT recipients with either early stent removal when attached to the Foley catheter or late removal via cystoscopy when unattached. Methods We conducted a multi‐center retrospective analysis of consecutive living donor KT patients (8/18/21‐4/21/23) stratified into Foley‐attached and unattached stent groups. Outcomes assessed were ureteral stricture, urine leaks, UTIs at 90 days and allograft failure and BKV DNAemia (BK virus DNAemia) at 1 year. Data are reported as mean and standard deviation. Results Among 247 patients with attached and 260 with unattached stents, baseline demographics (age, sex, diabetes) were similar between groups. There was a difference in race (87.9% vs. 77.8% Caucasian; p = 0.004). Foley catheters remained longer in the attached group (3.7 ± 1.8 vs. 3.0 ± 2.0 days; p < 0.001), but stents were removed earlier (3.7 ± 1.8 vs. 21.9 ± 4.7 days; p < 0.001). Comparing attached versus unattached, there were no differences in ureteral stricture (0.4% vs. 1.5%; p = 0.197), urine leak (0.8% vs. 0.4%; p = 0.533), BKV DNAemia (17.7% vs. 16.9%; p = 0.616), or allograft failure (0% vs. 0.8%; p = 0.167). However, UTI incidence by 90 days was lower in the attached group (5.7% vs. 11.9% p = 0.013). Induction therapy differed significantly between groups, with Alemtuzumab more common in the unattached group (58.1% vs. 19.4%, p < 0.001), Basiliximab more common in the attached group (43.3% vs. 35.0%, p < 0.001), and Thymoglobulin more common in the attached group (36.0% vs. 6.9%, p < 0.001). Baseline steroid use was higher in the unattached group (81.9% vs. 57.9%, p < 0.001). Conclusion Early stent removal via connection to the Foley catheter had similarly low rates of ureteral complications while reducing urinary tract infections and avoiding cystoscopic removal.

ABSTRACT Background and Objectives Neoadjuvant chemoimmunotherapy (NACI) for node‐positive breast cancer may induce immune cell activation in regional lymph nodes (LN), confounding post‐NACI imaging. Here we evaluated RECIST 1.1 criteria to predict post‐NACI pathologic LN status. Methods We studied patients with biopsy‐proven cN+ non‐distant metastatic breast cancer receiving NACI operated on 03/2020–09/2024 with both pre‐ and post‐NACI cross‐sectional imaging. Per RECIST 1.1, LN short axis diameter (SAD) was measured in target (defined as SAD ≥ 15 mm) and nontarget (SAD 10–14.9 mm) LNs. Groups were compared using Fisher′s exact test. Results 75 patients, median age 53 years, were studied: 61% cN1, 12% cN2, and 27% cN3. Baseline median number of imaging‐suspicious LN was 4 (IQR 2‐5). Post‐NACI, 64% had a nodal pathologic complete response (pCR/ypN0). 55% met RECIST 1.1 LN assessment criteria. 21 of 32 (66%) with an imaging CR (iCR) were ypN0, while 8 of 9 (89%) without an iCR were ypN0. Neither target ( p = 0.24) nor combined target/nontarget LN iCR ( p = 0.76) predicted ypN status. Nodal pCR rates were higher in those with ≤ 1 versus > 1 suspicious LN post‐NACI (71% vs. 42%, p = 0.03). Conclusions RECIST 1.1 criteria did not predict nodal pCR for NACI‐treated node‐positive breast cancer patients. Other post‐NACI imaging assessment strategies are needed.

Objectives: Electronic health records (EHR)-based triggers (eTriggers) have been used to study diagnostic errors in the emergency department (ED), often with suboptimal performance. Our objective was to investigate incremental value of multi-factor machine learning (ML) approaches to improve eTrigger performance. Methods: Patients presenting to an academic ED were categorized into trigger-positive and trigger-negative using standard trigger (T) definitions: (T1) ED return visits resulting in admission within 10 days; (T2) care escalation from the inpatient unit to the ICU within 24 hours; and (T3) deaths within 24 hours of admission. We trained and evaluated 6 supervised ML models. Results: A total of 124,053 consecutive encounters (5791 T-positive and 118,262 T-negative) were included. Among the T-positive, 4159 (72%) were associated with T1, 1415 (24%) with T2, and 217 (4%) with T3. The T-based positive predictive values (PPV) were 5.2% for T1, 8.2% for T2, and 6.5% for T3. ML models trained and evaluated on balanced training dataset and imbalanced test set had low classification performances (accuracy: 0.72–0.95; PPV: 0.00–0.16; F1-score: 0.00–0.23). Higher performances were observed in balanced test sets (accuracy: 0.80–0.97; PPV: 0.82–1.00; F1-score: 0.79–0.97). Comparing models trained on clinically annotated data with models trained on T-based labels identified other important factors. Conclusions: Utilizing machine learning to refine e-triggers slightly improves the identification of diagnostic errors, as evidenced by an increase in PPV values. We identified new potential factors contributing to ED diagnostic errors. These findings open new avenues to construct or modify more accurate e-triggers for diagnostic error identification.